We’re developing one:
TenoMiR®
A one-time injectable that can positively impact tendon health outcomes for patients of any age suffering from debilitating tendon pain – improving their quality of life every day
Leveraging a novel mechanism of action
TenoMiR® is a synthetic mimic of miR-29a, with enhanced stability, activity and cellular uptake. It targets the root molecular cause of tendinopathy.
Administration
Treatment with TenoMiR® does not require painful surgeries
Patient Experience
TenoMiR® is delivered directly into the damaged tendon via ultrasound-guided injection
Phase 2 Underway
A multi-site Phase 2 clinical trial is currently ongoing in the United States and United Kingdom.
Our Programs
We are exploring future therapeutic applications for microRNA technology, beyond tendinopathy, in high-value diseases including cardiovascular and skin-aging.
